Education
About Us
Working with TipRanks
Follow Us
Bioventix PLC (GB:BVXP)
LSE:BVXP
BVXP Stock Chart & Stats
Day’s Range― - ―
52-Week Range2,200.00p - 4,580.00p
Previous CloseN/A
Volume24.00
Average Volume (3M)9.01K
Market Cap
£150.21M
Enterprise ValueN/A
Total Cash (Recent Filing)£6.00M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)19.1
Beta0.29
Next Earnings
Oct 27, 2025Last Dividend Ex-Date
Apr 10, 2025Dividend Yield5.51%
Share Statistics
EPS (TTM)1.50
Shares Outstanding5,224,860
10 Day Avg. Volume7,343
30 Day Avg. Volume9,007
Financial Highlights & Ratios
PEG Ratio-2.51
Price to Book (P/B)11.20
Price to Sales (P/S)0.00
P/FCF Ratio15.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bioventix News
PremiumCompany Announcements
Bioventix CFO Increases Stake Through Share Purchase
PremiumCompany Announcements
Bioventix CEO Increases Stake with Option Exercise
PremiumCompany Announcements
Bioventix Reports Steady Revenue with Promising Future Prospects
PremiumCompany Announcements
Bioventix CFO Increases Stake Through Share PurchasePremiumCompany Announcements
Bioventix Triumphs at AGM; Strengthens Market Position
PremiumCompany Announcements
Bioventix Gains Increased Investment from Gresham House
PremiumCompany Announcements
Bioventix CFO Increases Stake in CompanyOptions Prices
Currently, No data available
---
Ownership Overview
5.81% Insiders
―
Mutual Funds
― Other Institutional Investors
94.19% Public Companies and
Individual Investors
BVXP FAQ
What was Bioventix PLC’s price range in the past 12 months?
Bioventix PLC lowest share price was 2200.00p and its highest was 4580.00p in the past 12 months.
What is Bioventix PLC’s market cap?
Bioventix PLC’s market cap is £150.21M.
When is Bioventix PLC’s upcoming earnings report date?
Bioventix PLC’s upcoming earnings report date is Oct 27, 2025 which is in 156 days.
How were Bioventix PLC’s earnings last quarter?
Bioventix PLC released its earnings results on Mar 31, 2025. The company reported 0.712p earnings per share for the quarter, beating the consensus estimate of N/A by 0.712p.
Is Bioventix PLC overvalued?
According to Wall Street analysts Bioventix PLC’s price is currently Overvalued.
Does Bioventix PLC pay dividends?
Bioventix PLC pays a Annually dividend of 156.999p which represents an annual dividend yield of 5.51%. See more information on Bioventix PLC dividends here
What is Bioventix PLC’s EPS estimate?
Bioventix PLC’s EPS estimate is 78.
How many shares outstanding does Bioventix PLC have?
Bioventix PLC has 5,224,860 shares outstanding.
What happened to Bioventix PLC’s price movement after its last earnings report?
Bioventix PLC reported an EPS of 0.712p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -12%.
Which hedge fund is a major shareholder of Bioventix PLC?
Currently, no hedge funds are holding shares in GB:BVXP
Bioventix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GB:BVXP Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth £10.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.75%
12-Months-Change
Fundamentals
Return on Equity
69.08%
Trailing 12-Months
Asset Growth
-1.05%
Trailing 12-Months
Company Description
Bioventix PLC
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.
Technical Analysis
Avacta Group plc
―
Oxford BioDynamics
―
Scancell Holdings
―
4basebio UK Societas
―
Arecor Therapeutics PLC
―